<div id="readability-page-1"><div><p>Health-care companies fell sharply as traders rotated into sectors more sensitive to changes in interest rates.</p><p>    Halozyme was granted a preliminary injunction that would prevent Merck &amp; Co. from distributing a formulation of Keytruda in Germany as part of a patent-infringement dispute over the cancer treatment. </p><p>    The Trump administration's ambition to unleash biomedical innovation and sharpen America's edge against China is colliding with a far messier reality inside the Food and Drug Administration, as Robert F. Kennedy Jr.'s revamping of American public health policy has inspired infighting and staff turnover, The Wall Street Journal reported. </p><p>   Write to Rob Curran at rob.curran@dowjones.com </p><p>    (END) Dow Jones Newswires</p><p>12-04-25 1738ET</p></div></div>

默克

奥洛兹美医疗

<p>医疗保健股票大幅下跌，因为交易者转向对利率敏感的行业。Halozyme 在与默克公司关于 Keytruda 的专利争议中获得了德国的初步禁令。特朗普政府的生物医学创新目标在 FDA 内部面临挑战，内部斗争和因罗伯特·F·肯尼迪 Jr. 的政策变化而导致的人员流动影响了这一进程</p>

由于资金转向对利率敏感的行业，医疗保健板块大幅下跌 -- 医疗保健综述